Abbott has launched its Proclaim™ DRG Neurostimulator System in the U.S.
According to the National Pain Foundation, one in four people in the world suffers from chronic pain and the condition is a key driver of visits to physician offices and a reduction in quality of life. complex regional pain syndrome (CRPS) is caused by a malfunction of the peripheral and central nervous systems due to injury, disease or trauma. The condition is one of the most difficult types of pain to treat because of its complexity in intensity and location.
Abbott’s new system is designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering from CRPS of the lower limbs.
The system is designed to provide patients new benefits over traditional neurostimulation systems, using Bluetooth® wireless technology, iOS! software and a more intuitive Apple! iPod touch! mobile digital device as its controller. The Proclaim DRG platform is magnetic resonance (MR)-conditional and recharge-free, offering upgradeability and increased battery capacity over Abbott’s previous generation systems.
“Both clinical and real world data have shown that DRG stimulation produces long-term, meaningful pain relief for patients with complex regional pain syndromes – like those resulting after total knee arthroplasty, foot surgery or hernia surgery,” said Timothy Deer, M.D., an interventional pain physician, president and chief executive officer of the Spine and Nerve Center of the Virginias in Charleston, West Virginia, and co-principal investigator of the ACCURATE study. “The ability to offer DRG stimulation on the Proclaim platform is a very exciting advancement for those of us who treat patients with these debilitating conditions and want to provide relief from hard-to-treat neuropathic conditions.”